Press Releases

Date Title and Summary View
Jun 11, 2024
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
May 13, 2024
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
May 09, 2024
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on
May 03, 2024
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD , May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Apr 03, 2024
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study,   as submitted in ASCO abstract Company plans to provide updated interim data, including safety and preliminary efficacy, by May 31 Company plans to provide additional clinical
Mar 07, 2024
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC Preclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and
Mar 01, 2024
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 27, 2024
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
ROCKVILLE, MD , Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Feb 02, 2024
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jan 08, 2024
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 06, 2023
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , Nov.
Nov 02, 2023
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Oct 31, 2023
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
ROCKVILLE, MD , Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Sep 05, 2023
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
ROCKVILLE, MD , Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc.
Aug 31, 2023
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate
Aug 09, 2023
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data from TZIELD®
Jul 31, 2023
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
ROCKVILLE, MD , July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
May 09, 2023
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine months Conference call
May 04, 2023
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
ROCKVILLE, MD , May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results
Apr 24, 2023
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Mar 22, 2023
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
ROCKVILLE, MD , March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S.
Mar 15, 2023
MacroGenics Provides Corporate Update and 2022 Financial Results
Cash runway extended through 2025 with $ 250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readout Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data presented at ASCO-GU
Mar 08, 2023
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
ROCKVILLE, MD , March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell
Mar 07, 2023
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Mar 02, 2023
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the